ImmunityBio Debt-to-Assets Ratio Growth & History (IBRX)

ImmunityBio's debt-to-assets ratio was 0.09 for fiscal 2025.

View full ImmunityBio company overview

ImmunityBio annual debt-to-assets ratio history

ImmunityBio annual debt-to-assets ratio

Fiscal yearPeriod endedDebt-to-assets ratioChangeGrowth
20252025-12-310.09−0.03−24.62%
20242024-12-310.110.02+26.75%
20232023-12-310.09−0.05−35.94%
20222022-12-310.140.05+63.83%
20212021-12-310.090.02+23.56%
20202020-12-310.07−0.03−29.74%
20192019-12-310.100.10
20182018-12-310.000.00
20172017-12-310.000.00
20162016-12-310.00

ImmunityBio debt-to-assets ratio trends

Over the last five fiscal years, ImmunityBio's debt-to-assets ratio increased from 0.07 to 0.09, a change of 0.02. The latest reported quarter, Q2 2026, shows 0.06.

About the metric

What the debt-to-assets ratio means

The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.

Calculation and source

How debt-to-assets is calculated

TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review ImmunityBio source filings ↗

Community posts

It’s quiet here.

No posts about IBRX yet. Start the conversation.

Write the first post